Upstream & Downstream Processing

Eurofins on how to get faster sterility results

Due to the 14-day incubation requirement for compendial sterility, this is often the last data available when testing BioPharmaceutical products for release or stability. So turnaround time pressure has always been an inherent part of sterility testing. This pressure has become more acute with the emergence of ATMPs, particularly autologous cell therapies which are often given to patients before traditional testing results can be obtained. Eurofins BioPharma Product Testing has responded to the demand for faster sterility results by streamlining…

Repligen eyes more M&A and expansions as demand continues to rocket

Repligen says it will both reinvest in its manufacturing network and look for M&A opportunities to feed the high demand for bioprocess consumables. For the full year 2020, bioprocessing tech firm Repligen Corporation reported sales of $366 million, up 36% year-on-year. The fourth quarter itself pulled in $108 million, representing a 56% increase on the same period 2019. As with fellow bioprocess vendors (Danaher, Sartorius, Thermo Fisher etc), COVID-19 played a major part in Repligen’s 2020 top line, with its…

Process intensification and PAT essential for achieving real-time release

Development of complex methods enabling real-time release of therapeutics requires creativity and collaboration, say experts from NIIMBL and SCIEX. Interest in real-time release (RTR) is driving the industry to think about process intensification in a coordinated manner. Process intensification offers the potential for increased efficiencies and thereby reduced cost and time for drug production. Workflows, capital and operating expenses, product quality, and waste production can all be positively impacted. There is consequently a push in the industry to develop and…

Affinity resins: Avitide gears up to support COVID-19 vaccine makers

Avitide says a specific SARS-CoV-2 virus spike protein affinity resin greatly helps the current COVID-19 efforts and could greatly accelerate the speed of response in future pandemics. Bioprocess service and consumable firms are looking to support the next wave of COVID-19 vaccines as they progress through the clinic. Last week, we reported that Repligen and Navigo launched an affinity resin specifically for the purification of COVID-19 vaccines. But they are not alone, and New Hampshire-based firm Avitide recently finalized its…

Repligen and Navigo target next-wave COVID vaccines with affinity resin

Repligen and Navigo have launched an affinity resin specifically for the purification of COVID-19 vaccines. Last year, bioprocess technology firm Repligen teamed with protein engineering firm Navigo Proteins GmbH to develop an affinity ligand specifically for COVID-19 vaccines. Like many COVID-19 vaccine and therapeutic efforts themselves, the collaboration plus speed of development have borne fruit with the firms launching the NGL COVID-19 Spike Protein Affinity Resin this week. While the handful of COVID-19 vaccines approved so far are not protein-based…

Thermo says COVID-19 vaccine and therapy work will generate $1bn in 2021

Thermo Fisher Scientific cited COVID-19 as a revenue driver in 2020 and predicted that pandemic-related work will make an even bigger contribution this year. Thermo’s revenues grew 26% in 2020 to $32.2 billion with COVID-19 testing and vaccine and therapy-related development activity generating $6.6 billion. The contribution from Thermo’s pharma and biotechnology business grew 25% in Q4 driven by increased demand for COVID-19 related bioproduction, pharma and bioscience services. Revenue from academic, government and industrial customers also increased as result…

Sartorius on target for €5bn sales by 2025

Sartorius has increased its 2025 target to €5 billion given robust financial results achieved in its Bioprocess Solutions (BPS) Division in 2020. Sartorius reported its Q4 2020 financials this week, revealing that total sales revenues rose to €2.3 billion ($2.8 billion) a 30% increase compared to 2019. The firm also told shareholders its order intake is up around 49% to 2.83 billion. The firm said its BPS division has experienced sharp rises in revenue and earnings, aided by its role…

Filling in its drug product offering: Cytiva buys Vanrx Pharmasystems

Cytiva’s first acquisition since being acquired by Danaher sees it add robotic aseptic filling machines to its bioprocess offering. Vanrx Pharmasystems, and all 120 staff, will be incorporated into Cytiva, after the bioprocess vendor acquired the Canadian company for an undisclosed fee. Vanrx makes standardized aseptic filling technologies for filling vials, syringes, and cartridges, including its SA25 range of aseptic and lyophilized technologies, and the Microcell Vial Filler – a closed robotic isolator for pharmaceutical vial filling. “For now, this…

Bioprocessing ‘running hot’ for Danaher with $1.3bn COVID windfall to come

Danaher Corporation reports double-digit sales growth at its bioprocess units Pall and Cytiva, inflated by COVID-related dividends it says will continue this year. For the full year 2020, Danaher Corporation reported net sales of $22.3 billion, a 24.5% increase on the previous year. Life sciences pulled in $10.6 billion of this, up 52% on 2019. While Danaher does not detail its individual business financial figures, the contributions from Cytiva – acquired for $21 billion last April –  and Pall Biotech…

Astrea licenses Avacta’s Affimer reagent technology

Gamma Biosciences’ bioseparation business Astrea will use the Affimer technology to expand its range of ligand discovery and development capabilities. Avacta Group’s Affimer reagents are small proteins that have a binding surface that can be tailored to capture a target molecule of interest out of complex mixtures encountered in biomanufacturing. “The Affimer reagent technology was originally developed at the MRC Cancer Unit in Cambridge UK for proteomics applications and was acquired by Avacta in 2012,” Alastair Smith, CEO of Avacta…